A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.
Saved in:
| Title: | A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. |
|---|---|
| Authors: | Kipps, Thomas J.1 (AUTHOR) tkipps@ucsd.edu, Eradat, Herbert2 (AUTHOR), Grosicki, Sebastian3 (AUTHOR), Catalano, John4 (AUTHOR), Cosolo, Walter5 (AUTHOR), Dyagil, Iryna S.6 (AUTHOR), Yalamanchili, Sreeni7 (AUTHOR), Chai, Akiko7 (AUTHOR), Sahasranaman, Srikumar7 (AUTHOR), Punnoose, Elizabeth7 (AUTHOR), Hurst, Deborah7 (AUTHOR), Pylypenko, Halyna8 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Oct2015, Vol. 56 Issue 10, p2826-2833. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
